CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04572451
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:30.958046+00:00
Published At: 2025-08-01T00:00:00+00:00
Record Updated At: 2025-08-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma", "Unresectable Solid Tumors", "Neoplasms", "Neoplasms by Histologic Type", "Neoplasms by Site", "Antineoplastic Agents, Immunological", "Antineoplastic Agents", "Immune Checkpoint Inhibitors", "Molecular Mechanisms of Pharmacological Action", "Nivolumab"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-01"
protocolSection.identificationModule.nctId: "NCT04572451"
protocolSection.identificationModule.officialTitle: "Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.